Funding Opportunities and Deadlines

Research Priority

Complications

Letter of Intent Due

December 10

Novel Therapeutic Strategies to Prevent or Delay Progression of Early Stage Diabetic Nephropathy

Details

Milestone Date Status
Letter of Intent Dec 10, 2019 Next
Application Jan 27, 2020
Award Notification Jul 31, 2020
Earliest Start Sep 30, 2020
Complications

Application Due
(Letter of Intent Required)

January 14

Novel Therapeutic Strategies to Prevent or Delay Progression of Early Stage Diabetic Retinopathy

Details

Milestone Date Status
Letter of Intent Required Nov 26, 2019 Passed
Application Jan 14, 2020 Next
Award Notification May 31, 2020
Earliest Start Jul 31, 2020
Metabolic Control

Application Due
(Letter of Intent Required)

January 08

Safe and Effective Use of SGLT Inhibitors for Type 1 Diabetes

Details

Milestone Date Status
Letter of Intent Required Oct 28, 2019 Passed
Application Jan 08, 2020 Next
Award Notification May 31, 2020
Earliest Start Aug 31, 2020
Prevention

Application Due
(Letter of Intent Required)

January 07

The Role of the Microbiome in Type 1 Diabetes: Pathogenesis and Therapeutic Utility

Details

Milestone Date Status
Letter of Intent Required Nov 06, 2019 Passed
Application Jan 07, 2020 Next
Award Notification Apr 30, 2020
Earliest Start Jul 01, 2020

Ongoing Opportunities

These funding sources are typically available annually or ongoing

JDRF Impact Grants

Conference Grants

Industry Discovery & Development Partnerships

Early-Career Patient-Oriented Diabetes Research Awards (projects in COMPLICATIONS are ineligible)
Jan 31

Career Development Awards (projects in COMPLICATIONS are ineligible)
Jan 31

Advanced Postdoctoral Fellowships (projects in COMPLICATIONS are ineligible)
Jan 31

Postdoctoral Fellowships (projects in COMPLICATIONS are ineligible)
Jan 31

Project Concepts (Strategic Research Agreement)
Feb 03

RFAs Awaiting Notification

Jan

Neoepitopes in Type 1 Diabetes: Pathogenesis, Staging, and Therapeutic Utility
Jan

Optimization and Clinical Validation of Islet Autoantibody Assays for Screening for Type One Diabetes Risk
Jan

Beta Cell Replacement Innovative Awards
Jan

Metabolic Control Innovative Awards
Jan

Immunotherapies Innovative Awards
Feb

Validation of T Cell Biomarkers and Assays for T1D
Mar

JDRF Diabetes Psychology Postdoctoral Fellowship Program
Mar

Telehealth in Type 1 Diabetes Behavioral Health and Psychology
Mar

Repositioning Drugs to Improve Metabolic Control in Established Type 1 Diabetes
Mar

Therapeutic Development and Clinical Testing of Immune Therapies for Type 1 Diabetes
Apr

3D Bioprinting and Biofabrication of Rationally Designed Engineered Tissue Constructs as Therapeutic Products for Treatment of Type 1 Diabetes (T1D)
May

Decoding Immune Mediated Diseases – Novel Approaches for Therapeutic Insights